Kake Life Sciences was selected as one of KPMG's "Top 50 Biotech Innovative Companies"

Recently, the award ceremony for KPMG China's "Top 50 Biotech Companies" was held simultaneously in Beijing, Shanghai, and Shenzhen.Kikai Life Sciences, a portfolio company of China Zhongji Investment, was successfully selected for the list due to its outstanding innovation capabilities.

The KPMG China Top 50 Biotech Innovation Companies list is organized by KPMG China and co-organized by CITIC Securities Co., Ltd. It received strong support and attention from expert representatives in the fields of scientific research, industry, investment, and business. Multiple external expert judges were invited,to conduct the selection based on five key core dimensions: the leading nature of technology and product lines, the richness of the product pipeline and the proportion of original products, the background of the core management and R&D teams, capital market activity, and financial health.The assessment covered companies in six major areas: biopharmaceuticals, cell therapy, gene therapy, in vitro diagnostics, medical devices, and drug research and development, selecting promising innovative biotech companies.

Since its launch in October 2022, the selection process, including registration, visits, and reviews, has lasted nearly half a year and the final results have been recently released.

△KPMG China's Second Top 50 Biotech Innovation Companies List

(The above list is sorted alphabetically by company abbreviation; ranking is not implied.)

Established in September 2018, Kikai (Nantong) Life Sciences Co., Ltd. is a high-end biopharmaceutical company specializing in the research, development, production, and sales of medical devices in the field of structural heart disease. It develops systematic solutions for valvular diseases catering to different populations, needs, and scenarios. The company's technical team is mainly composed of R&D personnel who have returned from the United States and Germany. They have many years of development and research experience in the field of cardiac medicine, and their technological level is leading in China and keeps pace with the forefront of advanced cardiac medical treatment in the world.

In recent years, Kikai Life Sciences has received continuous attention from the industry and the market. It has successively won the "Innovation Star" 2022 Shibei High-tech Zone Outstanding Contribution Award for Technological Innovation, was selected for the "2022 Investment界 Medical Health VENTURE50 List," and the "2022 China Biomedicine Technology Innovation Value List" series of lists including "Top 10 Most Growing Innovative Medical Device Companies." In the same year, it was selected for the Top 10 Most Growing New Economic Enterprises in China's Medical and Health Field by China Financing and Jiangsu Province's Potential Unicorn Enterprises; in 2021, it was selected for the Top 100 Chinese Innovative Medical Devices organized by the Zhong Nanshan Medical Foundation and the "2021 GEI China Potential Unicorn Enterprise List".

China Zhongji Investment completed its equity investment in Kikai Life Sciences in September 2021.

Links:

New Infrastructure Investment Professional Committee

Hebei Provincial Federation of Industry and Commerce

China Securities Investment Fund Association

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Mail： contact@zj-inv.cn

Career： zjtz-hr@zj-inv.cn

Report： ljjb@zj-inv.cn

Tel: 010-83272900 0311-87099959